MDACC Study No:2012-0262 ( NCT No: NCT01702155)
Title:A Phase I/II Study of DFP-10917 Given by Continuous Infusion in Patients with Relapsed or Refractory Acute Leukemia
Principal Investigator:Hagop Kantarjian
Treatment Agent:DFP-10917
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of DFP-10917 that can be given to patients with relapsed or refractory
leukemia. The safety of the study drug will also be tested.

DFP-10917 is designed to insert itself into the DNA of leukemia cells. It may
stop these cells from reproducing and may cause the DNA strands to break. This
may cause leukemia cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:DFP-10917
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Delta-Fly Pharma, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults